Clinical trial · people
Orforglipron: food lowered drug exposure by 17.6% to 23.7%
Checked against the paper Clinical trialPublished by PepVault
The takeaway
Food modestly lowered orforglipron blood levels in healthy adults, and the authors judged this unlikely to make a meaningful difference in its effect.
- Kind
- Clinical trial
- Studied in
- People
- Published
- 2024
- Journal
- Diabetes Ther
What they tested
Does taking orforglipron after eating instead of on an empty stomach change how much of the drug reaches the blood, and does it change safety?
How the study was done
Two phase 1 randomized crossover studies in healthy adults, where each person took the drug both fasted and fed. Study A gave a single 3 mg dose to 12 people, and study B gave repeated 16 mg doses to 34 people.

What they found
In the fed state, AUC (total drug exposure over time) was 23.7% lower and Cmax (peak blood level) was 23.2% lower in study A. In study B, AUC was 17.6% lower and Cmax was 20.9% lower with food. Half-life (how long the drug takes to clear by half) and the time to peak level were similar fed and fasted. Most side effects were gut-related, and there were no serious adverse events or deaths in either study.
What it doesn’t show
These were small, early-phase studies in healthy adults, and study B was 88.2% male. They measured blood levels and safety, not weight loss or blood sugar, so the authors' view that food won't change how well the drug works was not directly tested.
The paper
Ma et al. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024.
The compound
More studies on Orforglipron
- Orforglipron: heart events no worse than insulin in ACHIEVE-4Randomized trial · people · 2026
- Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Orforglipron 36 mg: 11.2% weight loss at 72 weeks in ATTAIN-1Randomized trial · people · 2025
- Every study on Orforglipron
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.